Pegfilgrastim

Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, [filgrastim]. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti-cancer treatment. It is grouped under the following drug class(es): Biologics. Its therapeutic use is listed as hematologic agents. The directory classifies it as a commercial API with a biotechnology source/manufacturing origin. Other names for this substance include Neulasta. Its PubChem CID is 70683024.

CAS No 208265-92-3
Molecular Formula C27H46N4O19
Molecular Weight 730.7 g/mol
Synonyms (2R,4S,5R,6R)-2-[[(2R,3R,4R,5R,6S)-5-acetamido-6-[(1S,2R)-1-amino-1-carboxypropan-2-yl]oxy-3,4-dihydroxyoxan-2-yl]methoxy]-4-hydroxy-5-[[2-(2-methoxyethoxycarbonylamino)acetyl]amino]-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid

Frequently Asked Questions